156TiP The LUNGVAC-study: A randomized phase II, open-label, multicenter study investigating efficacy and safety of anti-PD-1/PD-L1 treatment +/- UV1 vaccination as first-line treatment in patients with inoperable advanced or metastatic non-small cell lung cancer (NSCLC)
{"title":"156TiP The LUNGVAC-study: A randomized phase II, open-label, multicenter study investigating efficacy and safety of anti-PD-1/PD-L1 treatment +/- UV1 vaccination as first-line treatment in patients with inoperable advanced or metastatic non-small cell lung cancer (NSCLC)","authors":"E.M. Stensland, I.J.Z. Eide, O.T. Brustugun","doi":"10.1016/j.iotech.2023.100667","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":192507,"journal":{"name":"Immuno-Oncology and Technology","volume":"2 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immuno-Oncology and Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.iotech.2023.100667","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
